Yuan Liu

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 6

Top Topics

Epithelial Mesenchymal Transition

Ischemia Reperfusion Injury

Signaling Pathway

High Fat Diet Induced

Top Venues

Oxidative medicine and cellular longevity

Cardiovascular therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Lu Chen, Hongyu Su, Zekai Tao, Cui Liang, Zhongzhao Liu, Yiming Dong, Peipei Zheng, Yuan Liu
DUSP22 Ameliorates Endothelial-to-Mesenchymal Transition in HUVECs through Smad2/3 and MAPK Signaling Pathways. Cardiovascular therapeutics 2024 (2024)
Lu Chen, Hongyu Su, Zekai Tao, Cui Liang, Zhongzhao Liu, Yiming Dong, Peipei Zheng, Yuan Liu
DUSP22 Ameliorates Endothelial-to-Mesenchymal Transition in HUVECs through Smad2/3 and MAPK Signaling Pathways. Cardiovascular therapeutics 2024 (2024)
Lu Chen, Hongyu Su, Zekai Tao, Cui Liang, Zhongzhao Liu, Yiming Dong, Peipei Zheng, Yuan Liu
DUSP22 Ameliorates Endothelial-to-Mesenchymal Transition in HUVECs through Smad2/3 and MAPK Signaling Pathways. Cardiovascular therapeutics 2024 (2024)
Yuzhou Liu, Liying Zhou, Binbin Du, Yuan Liu, Junhui Xing, Sen Guo, Ling Li, Hongrui Chen
Protection against Doxorubicin-Related Cardiotoxicity by Jaceosidin Involves the Sirt1 Signaling Pathway. Oxidative medicine and cellular longevity 2021 (2021)
Yintao Zhao, Jingjing Sun, Wei Zhang, Meng Peng, Jun Chen, Lu Zheng, Xiangqin Zhang, Haibo Yang, Yuan Liu
Follistatin-Like 1 Protects against Doxorubicin-Induced Cardiomyopathy through Upregulation of Nrf2. Oxidative medicine and cellular longevity 2020 (2020)
Ran Li, Yuan Liu, Ying-Guang Shan, Lu Gao, Fang Wang, Chun-Guang Qiu
Bailcalin Protects against Diabetic Cardiomyopathy through Keap1/Nrf2/AMPK-Mediated Antioxidative and Lipid-Lowering Effects. Oxidative medicine and cellular longevity 2019 (2019)